MorphoSys and Lanthio Pharma acquires of Lanthio Pharma's lanthipeptide technology, which will be used for drug discovery by MorphoSys.The acquisition was triggered by MorphoSys exercising an option within an ongoing collaboration and option agreement between the two companies.

MorphoSys takes over the lanthipeptide technology and all related intellectual property.

Lanthio Pharma will continue to focus on building its portfolio of selected lanthipeptide drugs and will participate financially in MorphoSys's exploitation of the technology.

Financial details were not disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with Morphosys

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter